Ironwood Pharmaceuticals, Inc. Class A Common Stock IRWD
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERICi
Market dataready · fetched 2026-11-11T13:58:56.201Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T13:34:09.665501816Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T13:58:55.741582+00:00
Ironwood Pharmaceuticals, Inc. Class A Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 6.37 | 109.2% | 32.5% | 3.01 | 400.0% | 43.8% |
| 25Δ | 5.98 | 92.9% | 24.8% | 3.28 | 356.3% | 38.4% |
| 30Δ | 5.59 | 76.7% | 17.0% | 3.55 | 312.6% | 32.9% |
| 35Δ | 5.21 | 60.4% | 9.3% | 3.82 | 268.9% | 27.4% |
| 40Δ | 4.09 | 225.2% | 22.0% | |||
| 45Δ | 4.36 | 181.6% | 16.5% | |||
| 50Δ | 4.63 | 137.9% | 11.0% | |||
| 55Δ | 4.90 | 94.2% | 5.6% | |||
| 60Δ | 5.32 | 100.2% | 3.5% | |||
| 65Δ | 5.82 | 133.7% | 3.4% | |||
| 70Δ | 6.32 | 167.1% | 3.3% | |||
| 75Δ | 6.82 | 200.6% | 3.2% | |||
| 80Δ | 7.32 | 234.1% | 3.1% | |||
20Δ
- Pseudo strike
- 6.37
- IV
- 109.2%
- B/E move
- 32.5%
- Pseudo strike
- 3.01
- IV
- 400.0%
- B/E move
- 43.8%
25Δ
- Pseudo strike
- 5.98
- IV
- 92.9%
- B/E move
- 24.8%
- Pseudo strike
- 3.28
- IV
- 356.3%
- B/E move
- 38.4%
30Δ
- Pseudo strike
- 5.59
- IV
- 76.7%
- B/E move
- 17.0%
- Pseudo strike
- 3.55
- IV
- 312.6%
- B/E move
- 32.9%
35Δ
- Pseudo strike
- 5.21
- IV
- 60.4%
- B/E move
- 9.3%
- Pseudo strike
- 3.82
- IV
- 268.9%
- B/E move
- 27.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.09
- IV
- 225.2%
- B/E move
- 22.0%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.36
- IV
- 181.6%
- B/E move
- 16.5%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.63
- IV
- 137.9%
- B/E move
- 11.0%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.90
- IV
- 94.2%
- B/E move
- 5.6%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.32
- IV
- 100.2%
- B/E move
- 3.5%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.82
- IV
- 133.7%
- B/E move
- 3.4%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.32
- IV
- 167.1%
- B/E move
- 3.3%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.82
- IV
- 200.6%
- B/E move
- 3.2%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.32
- IV
- 234.1%
- B/E move
- 3.1%
Options history
No recorded observations
Drug Manufacturers - Specialty & Generic
KMDA
Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
More →KNSA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly…
More →LFCR
Lifecore Biomedical, Inc., is an integrated contract development and manufacturing organization in the United States and internationally. The company is headquartered in Santa…
More →LNTH
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer…
More →LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is…
More →NBIX
Description unavailable
More →